FDA approves an Eli Lilly NDA for Inluriyo (imlunestrant, 200 mg tablets), an oral estrogen receptor antagonist for treating certain adults with advan...
CBER posts 13 Form FDA-483s under the Freedom of Information Acts provision on frequently requested records.
FDA grants Biolinq a de novo authorization for its Shine system, said to be the first fully autonomous, needle-free glucose sensor.
FDA warns San Juan, Puerto Rico-based Cellebration LLC that it is violating the Federal Food, Drug, and Cosmetic Act and agency regulations by refusin...
Acadia Pharmaceuticals says it will cease developing intranasal carbetocin after its Phase 3 COMPASS PWS trial of the drug for treating hyperphagia in...
FDA publishes a draft guidance with recommendations for expedited development and review of regenerative medicine therapies for serious conditions.
FDA publishes a draft guidance on agency requirements and considerations for using various clinical trial designs and endpoints to support licensure o...
Reps. Pfluger and Landsman introduce bipartisan legislation to deem biosimilars to be interchangeable upon FDA approval.
